Cell Impact Q2 2026: Progress continues despite prolonged lead times

During the first half of the year, Cell Impact worked on a major transaction involving the sale of a large number of machines. The transaction was in the final stage of negotiations but was temporarily put on hold due to developments in the customer's project.

"The delay was one important reason for the financing measures we implemented during the quarter. We decided to conduct a rights issue of approximately SEK 53.6 million, before issue costs and repayment of bridge loans," said Daniel Vallin, CEO of Cell Impact.

Cell Impact's ambition remains unchanged: to create the necessary conditions to secure and deliver the major orders the company believes lie ahead, and to continue strengthening the position as a leading supplier of cost-efficient flow plates and related production solutions.

"By building up our expertise, processes and capacity, we have created a platform that is ready to handle increased volumes as customers take the next step in their projects. We are continuing to move forward, step by step, focusing on customer relationships, cost control and business activities that generate sales, cash flow and long-term value," Daniel Vallin concluded.

Financial summary:

• Net sales totaled SEK 1.4 million (2.1).
• The operating loss (EBIT) amounted to SEK -17.4 million (-20.0).
• The Group's loss after financial items was SEK -17.7 million (-21.2).
• Earnings per share attributable to the Parent Company's shareholders before and after dilution totaled SEK -0.04 (-0.03).
• Debt/equity ratio was 75 percent (78) on the balance sheet date.
• Cash flows from operating activities amounted to SEK -2.4 million (-11.9).
• On the balance sheet date, the Group's cash and cash equivalents totaled SEK 0.4 million (1.0). As of August 4, 2026, the cash balance amounted to SEK 2.9 million. 

This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.